Desentum

Developing novel types of allergen immunotherapy products (allergy vaccines)

placeEspoo, Uusimaa, Finland calendar_todayFounded 2011 groups6 employees language desentum.fi

Social engagement

Social engagement: 1.1K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

6 investors on record; lead investors include Cascara Ventures, Springvest, Voima Ventures.

Investor typeCountShare
Venture capital350%
Accelerator & incubator117%
Other / undisclosed233%

Hiring activity

Hires occasionally

3 roles tracked across 2 of the last 12 months

29 Jun 2026 · Quality Assurance and Regulatory Affairs Specialist · Finland

27 May 2026 · Preclinical Scientist

27 May 2026 · Project Lead

Based on job postings tracked across public sources.

Recent activity

9 Jun 2026
Event
World's largest allergy congress
28 Apr 2026
Milestone
regulatory
Coming soon